Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime
The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Summarize this article with
Foundayo (orforglipron), the first GLP-1 weight loss pill with no food, water, or timing restrictions, was FDA-approved on April 1, 2026, with a list price of $649/month. Clinical trials show 7.9-12.4% body weight loss depending on dose, and it's available through LillyDirect starting April 6, 2026. Made by Eli Lilly, Foundayo is a once-daily non-peptide small molecule, fundamentally different from every other GLP-1 on the market, approved under the FDA's National Priority Voucher program in just 50 days.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality.
Compare all 52GLP-1 providers →What Is Foundayo and Why Is It Different?
Foundayo (orforglipron) is a small-molecule, non-peptide GLP-1. Read our complete Foundayo guide for pricing, side effects, and where to buy, or compare it against the Wegovy pill receptor agonist. That technical description matters because every other GLP-1 on the market, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, is a peptide. Peptides are large, fragile molecules that your stomach acid destroys, which is why most GLP-1s require injection.
Oral Wegovy (approved December 2025) solved part of this problem by packaging the semaglutide peptide with an absorption enhancer (SNAC), but it still requires fasting, you must take it on an empty stomach with limited water and wait 30 minutes before eating. Foundayo has none of these restrictions because it's not a peptide at all. It's a completely different type of molecule that naturally survives digestion.
| Feature | Foundayo (orforglipron) | Oral Wegovy (semaglutide) | Injectable Wegovy | Injectable Zepbound |
|---|---|---|---|---|
| Type | Small molecule pill | Peptide pill | Peptide injection | Peptide injection |
| Dosing | Once daily, anytime | Once daily, fasting required | Once weekly injection | Once weekly injection |
| Food restrictions | None | 30-min fast required | N/A | N/A |
| Refrigeration | Not needed | Not needed | May be needed | May be needed |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk | Eli Lilly |
| FDA approved | April 1, 2026 | December 2025 | June 2021 | November 2023 |
Every Tuesday. One email. The cheapest verified GLP-1 programs of the week.
Price drops, FDA alerts, new programs ranked, and compounded shortages, delivered Tuesday morning. No filler. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
How Much Weight Can You Lose? Clinical Trial Results
Foundayo's clinical trials show meaningful weight loss, though less than the injectable GLP-1s. The key Phase 3 results from the ATTAIN-1 trial:
ATTAIN-1 trial (Phase 3, 72 weeks, adults with obesity/overweight):
| Dose | Weight Loss at 72 Weeks | Achieved 10%+ Loss | Achieved 15%+ Loss |
|---|---|---|---|
| 36 mg (highest) | -12.4% | 54.6% | 36.0% |
| 12 mg | -9.3% | N/A | N/A |
| 6 mg | -7.8% | N/A | N/A |
| Placebo | -2.1% | 12.9% | 5.9% |
In the head-to-head ACHIEVE-3 trial00202-3/abstract) (published in The Lancet, February 2026), orforglipron 36mg produced 73.6% greater weight loss than oral semaglutide 14mg over 52 weeks: -9.2% vs -5.3%. It also delivered superior blood sugar control (HbA1c reduction of -2.2% vs -1.4%).
Editor's Top Pick
Yucca Health
$146/mo · 7.7/10 · Compounded
Online weight-loss program by Yucca Health, Inc. (Beverly Hills, CA). Two named board-certified doctors, Dr. Michael Wasef MD and Dr. Andrew Sakla DO, handle prescribing. 20,000+ patients, 4.6 stars across 1,065 verified Trustpilot reviews. Starts at $146/mo for compounded semaglutide (custom-made version, not the FDA-approved brand) on the 6-month plan. Buy-now-pay-later via Klarna, Affirm, or Afterpay spreads the upfront commitment.
What Does Foundayo Cost?
| Coverage Scenario | Monthly Cost | How to Get It |
|---|---|---|
| Commercial insurance + savings card | As low as $25/mo | Foundayo savings card from Eli Lilly |
| Self-pay (lowest dose) | $149/mo | LillyDirect or retail pharmacy |
| Self-pay (higher doses) | Up to $399/mo | LillyDirect or retail pharmacy |
| Medicare Part D (July 2026+) | $50/mo | Medicare GLP-1 Bridge program |
| TrumpRx MFN pricing | ~$346/mo average | Included in Lilly MFN deal |
Foundayo is available in six tablet strengths: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg. Like all GLP-1s, you start at the lowest dose and gradually escalate. LillyDirect began shipping on April 6, 2026, with broader retail pharmacy availability following.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 52 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizSide Effects
The side effect profile is similar to other GLP-1s, primarily gastrointestinal, typically improving over time:
| Side Effect | Foundayo 36mg | Placebo |
|---|---|---|
| Nausea | 33.7% | 10.4% |
| Constipation | 25.4% | 9.3% |
| Diarrhea | 23.1% | 9.6% |
| Vomiting | 24.0% | 3.5% |
Discontinuation rates due to side effects were 10.3% at the highest dose vs 2.7% for placebo. About 59% of participants reported GI symptoms overall, though most were mild to moderate and improved during dose escalation. In the ACHIEVE-3 head-to-head trial, orforglipron had higher GI event rates than oral semaglutide (59% vs 37-45%).
Who Is Foundayo For?
Foundayo is approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related health condition, as an addition to diet and exercise, the same criteria as Wegovy and Zepbound.
It's most compelling for patients who:
- •Refuse or fear needles, the #1 barrier to GLP-1 adoption
- •Tried oral Wegovy but struggle with the fasting/timing requirements
- •Want a simpler daily routine, take it whenever, with coffee, with meals, doesn't matter
- •Travel frequently, no refrigeration, no injection supplies needed
- •Prefer Eli Lilly's ecosystem (same company as Zepbound/Mounjaro)
If maximum weight loss is your priority and you're comfortable with injections, Zepbound (~22% loss) or the upcoming retatrutide (~29% in trials) will likely deliver more. Foundayo's value is convenience and accessibility, not raw efficacy.
How to Get Foundayo
- •LillyDirect (direct from manufacturer): Shipping started April 6, 2026. Self-pay pricing from $149/mo.
- •Telehealth providers: Several providers on our rankings are expected to add Foundayo to their offerings in the coming weeks.
- •Retail pharmacies: Broader availability rolling out throughout April-May 2026.
- •Insurance: Check with your plan. Eli Lilly's savings card can reduce copays to $25/mo with commercial coverage.
Check our provider rankings to see which telehealth platforms offer Foundayo, or use our cost calculator to estimate what you'd pay with your specific insurance.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Find your GLP-1 program, our Top Pick is Yucca Health
Our featured pick, drawn from our independent ranking of 52 verified providers, at $146/mo all-in.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 52 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required
News & PipelineMedicare GLP-1 Coverage: Everything Changing in July 2026
News & PipelineFoundayo Ships Week 2: How to Order Eli Lilly's GLP-1 Pill Right Now (April 2026)
Keep exploring
- →Provider Rankings
- →Cheapest Providers
- →Take the Match Quiz
- →Weight Loss Predictor
- →Full Cost Guide
- →Cost Calculator
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
“People with overweight or obesity have individual preferences, and with oral semaglutide as a potential new treatment option, more of those who are not on treatment today may consider starting GLP-1 treatment.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.